Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
ConclusionGalcanezumab exhibited post-treatment efficacy for up to 4 months in Japanese patients with EM and with CM. No unexpected safety signals were observed.Clinical Trial RegistrationClinicalTrials.gov, NCT02959177 and NCT02959190.
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | Common Cold | Headache | Japan Health | Migraine | Neurology | Study